Request Demo
Recent blog posts
Latest Hotspot
8 min read
NCT07691515 Tislelizumab Biliary Tract Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07691515, evaluating Tislelizumab in Biliary Tract Cancer: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07689240 Pembrolizumab Clear Cell Renal Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07689240, evaluating Pembrolizumab in Clear Cell Renal Cell Carcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07639879 TR115 Peripheral T-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07639879, evaluating TR115 in Peripheral T-Cell Lymphoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Sutro Biopharma Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Sutro Biopharma 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
NCT07702578 TSC-101 Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07702578, evaluating TSC-101 in Acute Myeloid Leukemia: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07623161 Elritercept Myelofibrosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07623161, evaluating Elritercept in Myelofibrosis: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07700979 Cadonilimab Gastric and GEJ Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07700979, evaluating Cadonilimab in Gastric and GEJ Cancer: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07694427 Mocertatug Rezetecan Ovarian Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07694427, evaluating Mocertatug Rezetecan in Ovarian Cancer: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Mersana Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Mersana Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Recursion Pharmaceuticals Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Recursion Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Schrodinger Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Schrodinger 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Relay Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Relay Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.